title: Two-step targeting of urokinase to plasma clot provides efficient fibrinolysis.
abstract: Two-step targeting of urokinase to a model thrombus (human plasma clot) has been examined in vitro. To this purpose a covalent conjugate of vector antibodies to fibrinogen with monoclonal non-inhibiting antibody to urokinase was obtained using cross-linking agent disuccinimidilsuberate. After pretreatment with the conjugate clot acquired affinity for urokinase, which alters the character of fibrinolysis. Pretreatment with the conjugate resulted in at least 10-fold decrease in dose of urokinase needed for effective clot lysis (from 150 IU/ml for intact clot to 10-15 IU/ml for pretreated one). This variant of urokinase targeting provides effective clot lysis without fibrinogenolysis in plasma.
authors: Institute of Experimental Cardiology, Cardiology Research Center, Moscow, USSR.
authors: D V
authors: DV
authors: Sakharov
authors: V V
authors: VV
authors: Sinitsyn
authors: G A
authors: GA
authors: Kratasjuk
authors: N V
authors: NV
authors: Popov
authors: S P
authors: SP
authors: Domogatsky
mesh_terms: D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D005340:Fibrinogen / Q000276:immunology; D005342:Fibrinolysis / Q000187:drug effects*; D006801:Humans; D013927:Thrombosis / Q000188:drug therapy*; D014568:Urokinase-Type Plasminogen Activator / Q000627:therapeutic use*
chemical_list: D000911:Antibodies, Monoclonal; D005340:Fibrinogen; D014568:Urokinase-Type Plasminogen Activator